BACKGROUND: We investigated the association between the newly proposed International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification and (18)F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET), and whether the combination of these radiologic and pathologic factors can further prognostically stratify patients with stage I lung adenocarcinoma. METHODS: We retrospectively evaluated 222 patients with pathologic stage I lung adenocarcinoma who underwent FDG-PET scanning before undergoing surgical resection between 1999 and 2005. Patients were classified by histologic grade according to the IASLC/ATS/ERS classification (low, intermediate, or high grade) and by maximum standard uptake value (SUVmax) (low <3.0, high ≥3.0). The cumulative incidence of recurrence (CIR) was used to estimate recurrence probabilities. RESULTS: Patients with high-grade histology had higher risk of recurrence (5-year CIR, 29% [n = 25]) than those with intermediate-grade (13% [n = 181]) or low-grade (11% [n = 16]) histology (p = 0.046). High SUVmax was associated with high-grade histology (p < 0.001) and with increased risk of recurrence compared to low SUVmax (5-year CIR, 21% [n = 113] vs. 8% [n = 109]; p = 0.013). Among patients with intermediate-grade histology, those with high SUVmax had higher risk of recurrence than those with low SUVmax (5-year CIR, 19% [n = 87] vs. 7% [n = 94]; p = 0.033). SUVmax was associated with recurrence even after adjusting for pathologic stage (p = 0.037). CONCLUSIONS: SUVmax on FDG-PET correlates with the IASLC/ATS/ERS classification and can be used to stratify patients with intermediate-grade histology, the predominant histologic subtype, into two prognostic subsets.
BACKGROUND: We investigated the association between the newly proposed International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification and (18)F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET), and whether the combination of these radiologic and pathologic factors can further prognostically stratify patients with stage I lung adenocarcinoma. METHODS: We retrospectively evaluated 222 patients with pathologic stage I lung adenocarcinoma who underwent FDG-PET scanning before undergoing surgical resection between 1999 and 2005. Patients were classified by histologic grade according to the IASLC/ATS/ERS classification (low, intermediate, or high grade) and by maximum standard uptake value (SUVmax) (low <3.0, high ≥3.0). The cumulative incidence of recurrence (CIR) was used to estimate recurrence probabilities. RESULTS:Patients with high-grade histology had higher risk of recurrence (5-year CIR, 29% [n = 25]) than those with intermediate-grade (13% [n = 181]) or low-grade (11% [n = 16]) histology (p = 0.046). High SUVmax was associated with high-grade histology (p < 0.001) and with increased risk of recurrence compared to low SUVmax (5-year CIR, 21% [n = 113] vs. 8% [n = 109]; p = 0.013). Among patients with intermediate-grade histology, those with high SUVmax had higher risk of recurrence than those with low SUVmax (5-year CIR, 19% [n = 87] vs. 7% [n = 94]; p = 0.033). SUVmax was associated with recurrence even after adjusting for pathologic stage (p = 0.037). CONCLUSIONS: SUVmax on FDG-PET correlates with the IASLC/ATS/ERS classification and can be used to stratify patients with intermediate-grade histology, the predominant histologic subtype, into two prognostic subsets.
Authors: Robert James Cerfolio; Ayesha S Bryant; Buddhiwardhan Ohja; Alfred A Bartolucci Journal: J Thorac Cardiovasc Surg Date: 2005-07 Impact factor: 5.209
Authors: K Higashi; Y Ueda; M Yagishita; Y Arisaka; A Sakurai; M Oguchi; H Seki; Y Nambu; H Tonami; I Yamamoto Journal: J Nucl Med Date: 2000-01 Impact factor: 10.057
Authors: Hubert Vesselle; Joseph D Freeman; Linda Wiens; Joshua Stern; Huang Q Nguyen; Stephen E Hawes; Philip Bastian; Alexander Salskov; Eric Vallières; Douglas E Wood Journal: Clin Cancer Res Date: 2007-06-01 Impact factor: 12.531
Authors: Kyuichi Kadota; Yi-Chen Yeh; Jonathan Villena-Vargas; Leonid Cherkassky; Esther N Drill; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli Journal: Chest Date: 2015-09 Impact factor: 9.410
Authors: Jun-ichi Nitadori; Adam J Bograd; Kyuichi Kadota; Camelia S Sima; Nabil P Rizk; Eduardo A Morales; Valerie W Rusch; William D Travis; Prasad S Adusumilli Journal: J Natl Cancer Inst Date: 2013-08-07 Impact factor: 13.506
Authors: Kyuichi Kadota; Camelia S Sima; Maria E Arcila; Cyrus Hedvat; Mark G Kris; David R Jones; Prasad S Adusumilli; William D Travis Journal: Am J Surg Pathol Date: 2016-12 Impact factor: 6.394
Authors: Zachary A Kohutek; Abraham J Wu; Zhigang Zhang; Amanda Foster; Shaun U Din; Ellen D Yorke; Robert Downey; Kenneth E Rosenzweig; Wolfgang A Weber; Andreas Rimner Journal: Lung Cancer Date: 2015-05-28 Impact factor: 5.705
Authors: Marina Suárez-Piñera; José Belda-Sanchis; Alvaro Taus; Albert Sánchez-Font; Antoni Mestre-Fusco; Marcel Jiménez; Lara Pijuan Journal: Am J Nucl Med Mol Imaging Date: 2018-04-25